224 related articles for article (PubMed ID: 29788880)
21. Amorphous nano morin outperforms native molecule in anticancer activity and oral bioavailability.
Jangid AK; Agraval H; Gupta N; Jain P; Yadav UCS; Pooja D; Kulhari H
Drug Dev Ind Pharm; 2020 Jul; 46(7):1123-1132. PubMed ID: 32469607
[TBL] [Abstract][Full Text] [Related]
22. Nanosuspensions: a promising drug delivery strategy.
Patravale VB; Date AA; Kulkarni RM
J Pharm Pharmacol; 2004 Jul; 56(7):827-40. PubMed ID: 15233860
[TBL] [Abstract][Full Text] [Related]
23. Fabrication of an aprepitant nanosuspension using hydroxypropyl chitosan to increase the bioavailability.
Liu J; Li S; Ao W; Li Y; Xiao Y; Bai M
Biochem Biophys Res Commun; 2022 Nov; 631():72-77. PubMed ID: 36179498
[TBL] [Abstract][Full Text] [Related]
24. Development and evaluation of TPGS/PVA-based nanosuspension for enhancing dissolution and oral bioavailability of ticagrelor.
Na YG; Pham TMA; Byeon JJ; Kim MK; Han MG; Baek JS; Lee HK; Cho CW
Int J Pharm; 2020 May; 581():119287. PubMed ID: 32243963
[TBL] [Abstract][Full Text] [Related]
25. Diclofenac acid nanocrystals as an effective strategy to reduce in vivo skin inflammation by improving dermal drug bioavailability.
Pireddu R; Caddeo C; Valenti D; Marongiu F; Scano A; Ennas G; Lai F; Fadda AM; Sinico C
Colloids Surf B Biointerfaces; 2016 Jul; 143():64-70. PubMed ID: 26998867
[TBL] [Abstract][Full Text] [Related]
26. Nanocrystal for ocular drug delivery: hope or hype.
Sharma OP; Patel V; Mehta T
Drug Deliv Transl Res; 2016 Aug; 6(4):399-413. PubMed ID: 27165145
[TBL] [Abstract][Full Text] [Related]
27. A stable hydrocortisone nanosuspension for improved dissolution: Preparation, characterization and in vitro evaluation.
Ali HS; Khan S; York P; Shah SM; Khan J; Hussain Z; Khan BA
Pak J Pharm Sci; 2017 Sep; 30(5):1635-1643. PubMed ID: 29084684
[TBL] [Abstract][Full Text] [Related]
28. Formulation of dried lignans nanosuspension with high redispersibility to enhance stability, dissolution, and oral bioavailability.
Shen G; Cheng L; Wang LQ; Zhang LH; Shen BD; Liao WB; Li JJ; Zheng J; Xu R; Yuan HL
Chin J Nat Med; 2016 Oct; 14(10):757-768. PubMed ID: 28236405
[TBL] [Abstract][Full Text] [Related]
29. Nanosuspensions Containing Oridonin/HP-β-Cyclodextrin Inclusion Complexes for Oral Bioavailability Enhancement via Improved Dissolution and Permeability.
Zhang X; Zhang T; Lan Y; Wu B; Shi Z
AAPS PharmSciTech; 2016 Apr; 17(2):400-8. PubMed ID: 26187778
[TBL] [Abstract][Full Text] [Related]
30. Emerging Potential of Nanosuspension-Enabled Drug Delivery: An Overview.
Silki ; Sinha VR
Crit Rev Ther Drug Carrier Syst; 2015; 32(6):535-57. PubMed ID: 26559552
[TBL] [Abstract][Full Text] [Related]
31. Development of nanosuspension formulation for oral delivery of quercetin.
Sun M; Gao Y; Pei Y; Guo C; Li H; Cao F; Yu A; Zhai G
J Biomed Nanotechnol; 2010 Aug; 6(4):325-32. PubMed ID: 21323105
[TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo Evaluation of Ibuprofen Nanosuspensions for Enhanced Oral Bioavailability.
Hedaya M; Bandarkar F; Nada A
Med Princ Pract; 2021; 30(4):361-368. PubMed ID: 33823524
[TBL] [Abstract][Full Text] [Related]
33. Development and in vivo/in vitro evaluation of novel herpetrione nanosuspension.
Guo JJ; Yue PF; Lv JL; Han J; Fu SS; Jin SX; Jin SY; Yuan HL
Int J Pharm; 2013 Jan; 441(1-2):227-33. PubMed ID: 23220096
[TBL] [Abstract][Full Text] [Related]
34. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation.
Hong C; Dang Y; Lin G; Yao Y; Li G; Ji G; Shen H; Xie Y
Int J Pharm; 2014 Dec; 477(1-2):251-60. PubMed ID: 25445518
[TBL] [Abstract][Full Text] [Related]
35. Preparation and Characterization of Celecoxib Nanosuspension Using Bead Milling.
Kim HI; Jee JP; Kim ST; Kang D; Kim YC; Kim HC; Park SY; Lee HM; Cho KH; Kim DY; Choi SU; Jang DJ
J Nanosci Nanotechnol; 2019 Feb; 19(2):1184-1187. PubMed ID: 30360230
[TBL] [Abstract][Full Text] [Related]
36. Investigation of preparation parameters of nanosuspension by top-down media milling to improve the dissolution of poorly water-soluble glyburide.
Singh SK; Srinivasan KK; Gowthamarajan K; Singare DS; Prakash D; Gaikwad NB
Eur J Pharm Biopharm; 2011 Aug; 78(3):441-6. PubMed ID: 21439378
[TBL] [Abstract][Full Text] [Related]
37. Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box-Behnken Design.
Kassem MAA; ElMeshad AN; Fares AR
AAPS PharmSciTech; 2017 May; 18(4):983-996. PubMed ID: 27506564
[TBL] [Abstract][Full Text] [Related]
38. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability.
Nagaraj K; Narendar D; Kishan V
Drug Dev Ind Pharm; 2017 Jul; 43(7):1186-1196. PubMed ID: 28271908
[TBL] [Abstract][Full Text] [Related]
39. Formulation and evaluation of mucoadhesive buccal films impregnated with carvedilol nanosuspension: a potential approach for delivery of drugs having high first-pass metabolism.
Rana P; Murthy RS
Drug Deliv; 2013; 20(5):224-35. PubMed ID: 23651066
[TBL] [Abstract][Full Text] [Related]
40. A formulation strategy for gamma secretase inhibitor ELND006, a BCS class II compound: development of a nanosuspension formulation with improved oral bioavailability and reduced food effects in dogs.
Quinn K; Gullapalli RP; Merisko-Liversidge E; Goldbach E; Wong A; Liversidge GG; Hoffman W; Sauer JM; Bullock J; Tonn G
J Pharm Sci; 2012 Apr; 101(4):1462-74. PubMed ID: 22213574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
